Citable filing context
IDXX's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | IDEXX Laboratories reported Q2 2026 revenue of $1.217 billion, up 10%, and EPS of $4.27, up 18%. |
| May 15, 2026 | other | IDEXX shareholders approved amendments to declassify the board and allow 25% shareholders to call special meetings. |
| May 5, 2026 | earnings | IDEXX announced Q1 2026 revenue of $1,141 million and EPS of $3.47, raising its full-year 2026 guidance. |
| Aug 4, 2026 | Guidance: eps | 14.69 to 14.94 |
| Aug 4, 2026 | Guidance: operating_margin | 32.30 to 32.50 |
| Aug 4, 2026 | Guidance: revenue | 4700.00 to 4745.00 |
| Aug 4, 2026 | mda_quarterly | IDEXX Laboratories reported strong financial performance for the first half of 2026, driven primarily by its Companion Animal Group (CAG) segment. Total revenue reached $2.36 billion for the six months ended June 30, 2026, up from $2.11 billion in the prior-year period. CAG remains the primary growth engine, with recurring revenue—comprising IDEXX VetLab consumables, rapid assay products, and reference laboratory services—totaling $1.90 billion. The company maintains a robust liquidity position, supported by a $1.25 billion unsecured credit facility, with $729.2 million in remaining availability as of June 30, 2026. Capital allocation remains focused on share repurchases, with $703.7 million deployed for buybacks during the first half of 2026. Financial analysts should note the company’s reliance on multi-year customer commitment arrangements, which include significant contract assets ($332.6 million) and capitalized customer incentives ($271.8 million). While the company successfully resolved a $80 million legacy patent litigation in April 2025, it continues to manage risks related to macroeconomic volatility, geopolitical instability, and foreign currency fluctuations. IDEXX utilizes extensive hedging strategies, including cross-currency swaps and foreign exchange contracts, to mitigate exposure to the euro, British pound, Japanese yen, and other currencies. |
| May 5, 2026 | mda_quarterly | IDEXX reported total revenue of $1.14 billion for the first quarter of 2026, an increase from $998.4 million in the prior-year period. Growth was primarily driven by the Companion Animal Group (CAG), which generated $1.05 billion in revenue, led by IDEXX VetLab consumables ($412.6 million) and reference laboratory diagnostic services ($386.2 million). Net income rose to $278.4 million, resulting in diluted earnings per share of $3.47. The United States remains the primary market ($725.2 million), with significant contributions from Europe, the Middle East, and Africa ($257.1 million). The company continues aggressive capital allocation toward share repurchases, spending $371.4 million during the quarter. Strategic expansion included the $15.6 million acquisition of a U.S. reference laboratory's customer relationships in September 2025. Financial risks include exposure to geopolitical instability and hostilities in the Middle East, which may disrupt supply chains and increase operating costs in the Asia Pacific and European regions. To mitigate volatility, IDEXX employs foreign currency exchange contracts and interest rate swaps, including a hedge on a $250 million term loan effectively fixed at 3.4% plus a credit spread. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
IDXX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.